The phase II single‐arm LUN 14–179 study and the phase II DETERRED trial similarly assessed the safety and efficacy of consolidation therapy using pembrolizumab (anti‐PD‐1) or atezolizumab (anti‐PD‐L1) in patients with stage III unresectable NSCLC that did not exhibit disease progression following cCRT.12, 13. The gene discussed is CD274; the disease is non-small cell lung carcinoma.